REGN
Regeneron Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations S&P 500Nasdaq-100Russell 3000
$927.89Close
$599.96 – $927.8952-week range
Jan 30, 2027Next report · estimated
Highlights
Strengths
- Leading the market RS 85 · stronger than 85% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Earnings growing EPS +35% year on year, faster than the quarter before (+40 pts)
Cautions
- Trend not confirmed 7 of 8 conditions · 150-day under the 200-day
- Extended 5.8 ATR above its 50-day average
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 15.3%
price change
1mo
up 22.4%
price change
12-month return
up 43%
market up 11% ·
its own up 32%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 1%
year on year
EPS growth
up 35%
latest quarter · +40 pts
Sales growth
up 36%
latest quarter · +20 pts
ROE
up 15%
return on equity
Free cash margin
up 28%
$4.1B FCF
D/E
0.06
long-term debt / equity
Net debt / EBITDA
-0.3×
net cash
Interest cover
—EBIT / interest
Trade setup
ATR%
2.9%
$27.10 a day · 2×ATR $873.70
RS
85 / 99
vs the universe
Trend
7 / 8
150-day under the 200-day
Relative volume
4.2×
vs 50-day average
Up/down volume
1.01
50 sessions
Implied move
—
no scheduled report
Trend template · 7 of 8
- 150-day average above the 200-day: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 30, 2026
Results reaction
Oct 30, 2026+15% vs market2 sessions after results
Options
$25.4M33.6% IV · activity
Financials
- Net 31%
- Free cash 28%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Operating income | $3.6B | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B |
| Net income | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B |
| Net margin | 41% | 50% | 36% | 30% | 31% | 31% |
| Earnings per share | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Free cash flow | $2.0B | $6.5B | $4.4B | $3.9B | $3.7B | $4.1B |
| Free cash margin | 24% | 41% | 36% | 30% | 26% | 28% |
| Cash | $2.2B | $2.9B | $3.1B | $2.7B | $2.5B | $3.1B |
| Long-term debt | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B |
| Shareholders' equity | $11.0B | $18.8B | $22.7B | $26.0B | $29.4B | $31.3B |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $857 – $995 ±7.4% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Smaller 33.6% priced · 48.4% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs more
Positioning
- Premium traded
- $25.4M calls $23.1M · puts $2.3M · latest session
- 0.10× -1.77 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +296 · puts +1.53k past week
For options traders: ATM IV 33.6% (-3.0% 1w) · 1m ÷ 3m IV 1.03 · 25Δ skew 2.0 pts · Net GEX $22.3M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Apr 29, 2026 | Quarterly ↗ | Mar 31, 2026 | 29d |
| Feb 4, 2026 | Annual ↗ | Dec 31, 2025 | 35d |
| Oct 28, 2025 | Quarterly ↗ | Sep 30, 2025 | 28d |
| Aug 1, 2025 | Quarterly ↗ | Jun 30, 2025 | 32d |
| Apr 29, 2025 | Quarterly ↗ | Mar 31, 2025 | 29d |
| Feb 5, 2025 | Annual ↗ | Dec 31, 2024 | 36d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 5, 2024 | Annual ↗ | Dec 31, 2023 | 36d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 30, 2026 | Results ↗ |
| Oct 6, 2026 | Material agreement · Results · Other events ↗ |
| Sep 30, 2026 | Director or officer change ↗ |
| Jul 30, 2026 | Results ↗ |
| Jul 6, 2026 | Results ↗ |
| Jun 17, 2026 | Shareholder vote ↗ |
| Apr 29, 2026 | Results ↗ |
| Apr 8, 2026 | Results ↗ |
| Jan 30, 2026 | Results ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Oct 28, 2025 | Results ↗ |
| Oct 6, 2025 | Results ↗ |